Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous injection use. It is employed to prevent and treat venous thromboembolic disorders such as deep‑vein thrombosis and pulmonary embolism in adult patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, is used in the management of venous thromboembolism. - Prevention of deep‑vein thrombosis (DVT) in surgical patients: reduces the incidence of postoperative clot formation. - Acute deep‑vein thrombosis: facilitates clot resolution and prevents extension of the thrombus. - Pulmonary embolism: treats existing emboli and lowers the risk of recurrence.

Adverse reactions to Innohep may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Bruising or hematoma at the injection site. - Mild bleeding (e.g., gum or nosebleeds). - Nausea. - Headache. - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Major bleeding (intracranial, gastrointestinal). - Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT). - Severe allergic reactions (anaphylaxis, urticaria). - Spinal or epidural hematoma. - Skin necrosis at injection sites. - Disseminated intravascular coagulation (rare).

When using Innohep, consider the following precautions: - Renal impairment: adjust dose or monitor renal function closely. - History of heparin‑induced thrombocytopenia: avoid use. - Concurrent anticoagulants: increased risk of bleeding; monitor coagulation parameters. - Recent surgery or trauma: assess bleeding risk before administration. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep may interact with several drug classes; monitoring and avoidance are advised where appropriate.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): high bleeding risk. - Thrombolytic agents (e.g., alteplase, tenecteplase): additive hemorrhagic effect. - Therapeutic‑dose antiplatelet drugs (e.g., clopidogrel, ticagrelor): severe bleeding potential.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): increased minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: potential for enhanced bleeding. - Renal dysfunction affecting drug clearance: dose adjustment and monitoring required.